Companies will discover and develop novel targets for the potential treatment of neuropsychiatric conditions New discovery program builds upon nearly two decades of partnership between AbbVie and Gedeon RichterNORTH CHICAGO, Ill. and BUDAPEST, Hungary, Oct. 24, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Gedeon Richter Plc.

2024年10月24日，公司将发现并开发神经精神疾病潜在治疗的新目标。新发现计划建立在艾伯维与伊利诺伊州芝加哥Gedeon RichterNORTH和匈牙利布达佩斯的近二十年合作关系的基础上。

('Richter') today announced a new discovery, co-development and license agreement to advance novel targets for the potential treatment of neuropsychiatric conditions. This collaboration expands upon the success of nearly two decades of partnership on central nervous system (CNS) projects, including globally launched products such as cariprazine (VRAYLAR® / REAGILA®) and the discovery of investigational drug candidate ABBV-932 for the treatment of bipolar depression and generalized anxiety disorder..

（“里希特”）今天宣布了一项新发现、共同开发和许可协议，以推进神经精神疾病潜在治疗的新目标。这项合作扩大了近二十年中枢神经系统（CNS）项目合作的成功，包括全球推出的产品，如卡利嗪（VRAYLAR®/REAGILA®），以及发现用于治疗双相抑郁和广泛性焦虑症的研究候选药物ABBV-932。

'There remains a large unmet need for people living with neuropsychiatric disorders, making it imperative that we continue to innovate and pursue novel targets and approaches to discover and develop new therapies,' said Jonathon Sedgwick, Ph.D., senior vice president and global head of discovery research, AbbVie.

AbbVie高级副总裁兼发现研究全球负责人乔纳森·塞奇威克（JonathonSedgwick）博士说：“对于患有神经精神疾病的人来说，仍然存在大量未满足的需求，因此我们必须继续创新和追求新的目标和方法，以发现和开发新的疗法。”

'We are excited to expand our longstanding and successful partnership with Richter to help address the complex needs of these patients.'.

“我们很高兴与里希特扩大长期而成功的合作关系，以帮助解决这些患者的复杂需求。”

'This new agreement builds on years of successful partnership allowing Richter to further support AbbVie's global ambition in neuropsychiatry and validates the quality of science behind our unique discovery platform,' said Gábor Orbán, chief executive officer of Gedeon Richter.

Gedeon Richter首席执行官Gábor Orbán说：“这项新协议建立在多年成功合作的基础上，使Richter能够进一步支持AbbVie在神经精神病学领域的全球雄心，并验证我们独特发现平台背后的科学质量。”。

Under the terms of the agreement, the collaboration includes both preclinical and clinical R&D activities with shared financing by the parties. Richter will receive an upfront cash payment of $25 million, along with potential future development, regulatory and commercialization milestones. In addition, Richter may also receive sales-based royalties.

根据协议条款，合作包括临床前和临床研发活动，双方共同出资。里希特将获得2500万美元的预付现金，以及潜在的未来发展、监管和商业化里程碑。此外，里希特还可能收到基于销售额的版税。

AbbVie will have worldwide commercialization rights except for traditional markets of Richter, such as geographic Europe, Russia, other CIS countries and Vietnam..

AbbVie将拥有除里氏传统市场（如欧洲、俄罗斯、其他独联体国家和越南）以外的全球商业化权利。

About AbbVie

关于AbbVie

AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas – immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio.

我们致力于在免疫学、肿瘤学、神经科学和眼部护理等几个关键治疗领域，以及Allergan美学产品组合中的产品和服务，对人们的生活产生重大影响。

About Gedeon Richter

关于Gedeon Richter

Gedeon Richter Plc. (www.gedeonrichter.com), headquartered in Budapest/Hungary, is a major pharmaceutical company in Central Eastern Europe, with an expanding direct presence in Western Europe, China, Latin America, and Australia. Having reached a market capitalization of EUR 4.3bn (USD 4.7bn) by the end of 2023, Richter's consolidated sales were approximately EUR 2.1bn (USD 2.3bn) during the same year.

Gedeon Richter公司。总部位于匈牙利布达佩斯，是中东欧的一家大型制药公司，在西欧、中国、拉丁美洲和澳大利亚的直接业务不断扩大。截至2023年底，Richter的市值达到43亿欧元（47亿美元），同年的合并销售额约为21亿欧元（23亿美元）。

The product portfolio of Richter covers many important therapeutic areas, including Women's Healthcare, Central Nervous System, and Cardiovascular areas. Having the largest R&D unit in Central Eastern Europe, Richter's original research activity focuses on CNS disorders. With its widely acknowledged steroid chemistry expertise, Richter is a significant player in the Women's Healthcare field worldwide.

Richter的产品组合涵盖了许多重要的治疗领域，包括女性保健、中枢神经系统和心血管领域。里希特拥有中东欧最大的研发部门，其最初的研究活动专注于中枢神经系统疾病。凭借其广为人知的类固醇化学专业知识，里希特在全球女性保健领域发挥着重要作用。

Richter is also active in biosimilar product development, manufacture and commercialization..

里希特还积极参与生物仿制药产品的开发、制造和商业化。。